期刊
CHEST
卷 139, 期 1, 页码 190-193出版社
ELSEVIER SCIENCE BV
DOI: 10.1378/chest.10-0128
关键词
-
资金
- GlaxoSmithKline (GSK)
- AstraZeneca
- Nycomed
- Dutch Asthma Foundation
- Zorg Onderzoek Nederland Medische Wetenschappen
It is now well recognized that treatment with anti-IgE antibodies like omalizumab is a valuable option in patients with allergic asthma who remain symptomatic despite optimal treatment. To our knowledge, treatment with omalizumab in patients with nonallergic asthma has not been reported. We present and discuss a patient with severe asthma and elevated total IgE who had a negative radioallergosorbent (RAST) test result and a negative skin-prick test result; the patient showed a dramatic improvement with this treatment strategy. CHEST 2011; 139(1):190-193
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据